NO20030128L - Treatment of B cell malignancy using combination of B cell-reducing antibody and immunomodulatory antibody related applications - Google Patents
Treatment of B cell malignancy using combination of B cell-reducing antibody and immunomodulatory antibody related applicationsInfo
- Publication number
- NO20030128L NO20030128L NO20030128A NO20030128A NO20030128L NO 20030128 L NO20030128 L NO 20030128L NO 20030128 A NO20030128 A NO 20030128A NO 20030128 A NO20030128 A NO 20030128A NO 20030128 L NO20030128 L NO 20030128L
- Authority
- NO
- Norway
- Prior art keywords
- cell
- antibody
- treatment
- combination
- related applications
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21770600P | 2000-07-12 | 2000-07-12 | |
US09/772,938 US20020006404A1 (en) | 1999-11-08 | 2001-01-31 | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
PCT/US2001/015677 WO2002004021A1 (en) | 2000-07-12 | 2001-05-16 | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20030128D0 NO20030128D0 (en) | 2003-01-10 |
NO20030128L true NO20030128L (en) | 2003-03-12 |
Family
ID=26912176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20030128A NO20030128L (en) | 2000-07-12 | 2003-01-10 | Treatment of B cell malignancy using combination of B cell-reducing antibody and immunomodulatory antibody related applications |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1305045A1 (en) |
JP (1) | JP2004502742A (en) |
KR (2) | KR20030031957A (en) |
CN (1) | CN1446104A (en) |
AU (2) | AU2001264612C1 (en) |
CA (1) | CA2415100A1 (en) |
IL (1) | IL153764A0 (en) |
MX (1) | MXPA03000306A (en) |
NO (1) | NO20030128L (en) |
SG (1) | SG136804A1 (en) |
WO (1) | WO2002004021A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1642596A3 (en) | 1999-05-07 | 2006-04-12 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
EP1299128A2 (en) * | 2000-06-20 | 2003-04-09 | Idec Pharmaceuticals Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
KR20040023565A (en) * | 2000-09-18 | 2004-03-18 | 아이덱 파마슈티칼즈 코포레이션 | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
CN1308448C (en) | 2000-10-20 | 2007-04-04 | 中外制药株式会社 | Degraded TPO agonist antibody |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
AU2002243718B2 (en) * | 2001-01-31 | 2007-12-06 | Biogen Idec Inc. | Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
WO2002078766A2 (en) * | 2001-04-02 | 2002-10-10 | Genentech, Inc. | Combination therapy |
AU2003210266A1 (en) * | 2002-02-14 | 2003-09-04 | Bioinvent International Ab | Treatment, diagnosis and imaging of disease |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
KR20100050587A (en) | 2002-10-17 | 2010-05-13 | 젠맵 에이/에스 | Human monoclonal antibodies against cd20 |
JP4351674B2 (en) | 2002-12-16 | 2009-10-28 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants and their use and use |
JP2004279086A (en) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | Radiation image conversion panel and method for manufacturing it |
JPWO2004087763A1 (en) * | 2003-03-31 | 2006-07-27 | 中外製薬株式会社 | Modified antibody against CD22 and use thereof |
RS51686B (en) | 2003-04-09 | 2011-10-31 | Genentech Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
PT1631313E (en) | 2003-06-05 | 2015-07-02 | Genentech Inc | Combination therapy for b cell disorders |
BRPI0415457A (en) | 2003-10-16 | 2006-12-05 | Micromet Ag | cytotoxically active cd3 specific binding construct, its production process, composition comprising the same, nucleic acid sequence, vector, host, its uses in the preparation of a pharmaceutical composition and kit comprising the same |
EP2236172A1 (en) * | 2003-11-04 | 2010-10-06 | Novartis Vaccines and Diagnostics, Inc. | Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
TW201422238A (en) | 2004-06-04 | 2014-06-16 | Genentech Inc | Use of CD20 antibody in treatment of multiple sclerosis and an article for the use |
US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
AU2006214121B9 (en) * | 2005-02-15 | 2013-02-14 | Duke University | Anti-CD19 antibodies and uses in oncology |
KR101374454B1 (en) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | Methods for producing polypeptides by regulating polypeptide association |
TW200722518A (en) | 2005-03-31 | 2007-06-16 | Chugai Pharmaceutical Co Ltd | Sc(fv)2 structural isomers |
JP5129122B2 (en) | 2005-04-26 | 2013-01-23 | トリオン ファーマ ゲーエムベーハー | Combination of antibodies and glucocorticoids for cancer treatment |
JP5085322B2 (en) | 2005-06-10 | 2012-11-28 | 中外製薬株式会社 | Pharmaceutical composition containing sc (Fv) 2 |
JP5068167B2 (en) | 2005-06-10 | 2012-11-07 | 中外製薬株式会社 | Stabilizer for protein preparation containing meglumine and use thereof |
CN105012953B (en) | 2005-07-25 | 2018-06-22 | 阿普泰沃研发有限责任公司 | B- cells are reduced with CD37- specificity and CD20- specific binding molecules |
JP2009502936A (en) | 2005-07-25 | 2009-01-29 | トルビオン ファーマシューティカルズ, インコーポレイテッド | Single dose of CD20 specific binding molecule |
WO2007019865A2 (en) | 2005-08-18 | 2007-02-22 | Genmab A/S | Therapy with cd4 binding peptides and radiation |
ES2400660T3 (en) | 2005-11-01 | 2013-04-11 | Novartis Ag | Uses of anti-CD40 antibodies |
AU2006318539B2 (en) | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
BRPI0710826A2 (en) | 2006-04-21 | 2011-08-23 | Novartis Ag | antagonist anti-cd40 antibody pharmaceutical compositions |
CA2654317A1 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
AU2008275229B2 (en) | 2007-07-09 | 2014-11-06 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
AU2008312406B2 (en) | 2007-10-16 | 2014-03-06 | Ares Trading S.A. | Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease |
US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
EP2365003A1 (en) | 2008-04-11 | 2011-09-14 | Emergent Product Development Seattle, LLC | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
TW201438738A (en) | 2008-09-16 | 2014-10-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
RU2639288C2 (en) | 2009-08-11 | 2017-12-20 | Дженентек, Инк. | Proteins production in cultural media without glutamine |
RU2573994C2 (en) | 2010-02-10 | 2016-01-27 | Иммьюноджен, Инк | Anti-cd20 antibodies and thereof application |
ES2748347T3 (en) | 2010-03-12 | 2020-03-16 | Debiopharm Int Sa | CD37 binding molecules and immunoconjugates thereof |
AR083847A1 (en) | 2010-11-15 | 2013-03-27 | Novartis Ag | FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES |
JP6534615B2 (en) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | Method for producing polypeptide heteromultimer |
MA41459A (en) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS |
AU2016276158B2 (en) | 2015-06-08 | 2022-06-30 | Debiopharm International, S.A. | Anti-CD37 immunoconjugate and anti-CD20 antibody combinations |
LT3313879T (en) | 2015-06-24 | 2022-03-25 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
BR112018003147A2 (en) | 2015-08-28 | 2018-09-18 | Debiopharm International S.A. | cd37 antibodies and testing |
EA201890613A1 (en) | 2015-09-21 | 2018-10-31 | Аптево Рисёрч Энд Девелопмент Ллс | POLYPEPTIDES CONNECTING CD3 |
NZ741067A (en) | 2015-10-02 | 2023-07-28 | Hoffmann La Roche | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
CA3003399A1 (en) | 2015-11-02 | 2017-05-11 | Bioatla, Llc | Conditionally active polypeptides |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of fc region-containing polypeptide |
US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
GB2578037A (en) | 2017-05-24 | 2020-04-15 | Als Therapy Development Inst | Therapeutic anti-CD40 ligand antibodies |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2091684T3 (en) * | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | THERAPEUTIC APPLICATION OF CHEMICAL AND RADIO-MARKED ANTIBODIES AGAINST THE RESTRICTED DIFFERENTIATION ANTIGEN OF HUMAN B-LYMPHOCYTES FOR THE TREATMENT OF B-CELL LYMPHOMA. |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
-
2001
- 2001-05-16 MX MXPA03000306A patent/MXPA03000306A/en not_active Application Discontinuation
- 2001-05-16 IL IL15376401A patent/IL153764A0/en unknown
- 2001-05-16 EP EP01939050A patent/EP1305045A1/en not_active Withdrawn
- 2001-05-16 CA CA002415100A patent/CA2415100A1/en not_active Abandoned
- 2001-05-16 KR KR10-2003-7000429A patent/KR20030031957A/en not_active Application Discontinuation
- 2001-05-16 WO PCT/US2001/015677 patent/WO2002004021A1/en active IP Right Grant
- 2001-05-16 CN CN01814063A patent/CN1446104A/en active Pending
- 2001-05-16 KR KR1020087009742A patent/KR20080039547A/en not_active Application Discontinuation
- 2001-05-16 AU AU2001264612A patent/AU2001264612C1/en not_active Ceased
- 2001-05-16 AU AU6461201A patent/AU6461201A/en active Pending
- 2001-05-16 SG SG200500152-4A patent/SG136804A1/en unknown
- 2001-05-16 JP JP2002508475A patent/JP2004502742A/en not_active Abandoned
-
2003
- 2003-01-10 NO NO20030128A patent/NO20030128L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20080039547A (en) | 2008-05-07 |
MXPA03000306A (en) | 2004-04-05 |
EP1305045A1 (en) | 2003-05-02 |
WO2002004021A9 (en) | 2003-01-16 |
AU6461201A (en) | 2002-01-21 |
SG136804A1 (en) | 2007-11-29 |
CN1446104A (en) | 2003-10-01 |
CA2415100A1 (en) | 2002-01-17 |
AU2001264612B2 (en) | 2007-02-22 |
AU2001264612B8 (en) | 2007-02-22 |
NO20030128D0 (en) | 2003-01-10 |
JP2004502742A (en) | 2004-01-29 |
KR20030031957A (en) | 2003-04-23 |
IL153764A0 (en) | 2003-07-06 |
AU2001264612C1 (en) | 2007-11-22 |
WO2002004021A1 (en) | 2002-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20030128D0 (en) | Treatment of B cell malignancy using combination of B cell-reducing antibody and immunomodulatory antibody related applications | |
DK1604680T3 (en) | Use of butulinum toxin in the treatment of neuralgic pain | |
DK1390389T3 (en) | Crypto-blocking antibodies and uses thereof | |
NO20024874D0 (en) | Benzoamide piperidine-containing compounds and related compounds | |
DE50112013D1 (en) | DEODORANTIA AND ANTIPERSPIRANTIES | |
NO20001446L (en) | Methods and devices at submarine production facilities | |
NO20011964L (en) | Well treatment fluids and methods for using them | |
DE60132052D1 (en) | Drilling and treatment fluids | |
NO20022334L (en) | New composition and application | |
NO20020781D0 (en) | Device and methods of production / injection pipeline | |
NO20034437L (en) | Ganglioside-associated recombinant antibodies and their use in the diagnosis and treatment of tumors | |
NO20030397L (en) | Amyloid targeting imaging agents and uses of the same | |
DK1216046T3 (en) | Hitherto unknown combination of loteprednol and antihistamines | |
ATE285951T1 (en) | ORGINALITY CLOSURE AND MANUFACTURING PROCESS | |
NO20024404D0 (en) | Improvements in and regarding corrosion investigation | |
NO20033854L (en) | N-but-3-enyl-norbuprenorphine and methods of use | |
IS6401A (en) | Chemical methods and intermediates | |
NO20030882L (en) | Glass ceramic pulp and its use | |
DE60120291D1 (en) | Endoscope and endoscope capsule | |
NO20020031D0 (en) | Dihydrobenzodiazepines and their use in the treatment of dyslipidemia | |
DE60138593D1 (en) | Distortion compensation method and device | |
NO20001954L (en) | Separator Methods and Devices | |
ITMI20011942A0 (en) | FORMING DEVICE AND PROCEDURE ESPECIALLY WITH HYDRAULIC CLOSING DEVICE | |
NO20024617D0 (en) | Aryl and heteroarylsulfonates | |
NO20006537D0 (en) | Method and arrangement of bottom detector |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |